Enfortumab Vedotin/Pembrolizumab Improved Survival Vs Surgery in MIBC
Patients with cisplatin-ineligible bladder cancer who received enfortumab vedotin plus pembrolizumab and surgery had prolonged survival vs those who received surgery alone.